510
Participants
Start Date
November 28, 2019
Primary Completion Date
December 13, 2020
Study Completion Date
December 13, 2020
Norovirus Bivalent (GI.1 / GII.4) Vaccine（low）
Norovirus Bivalent (GI.1 / GII.4) Vaccine（low）administered intramuscularly according to a 0, 28，（56） day vaccination schedule
Norovirus Bivalent (GI.1 / GII.4) Vaccine（middle）
Norovirus Bivalent (GI.1 / GII.4) Vaccine（middle）administered intramuscularly according to a 0, 28，（56） day vaccination schedule
Norovirus Bivalent (GI.1 / GII.4) Vaccine（high）
Norovirus Bivalent (GI.1 / GII.4) Vaccine（high）administered intramuscularly according to a 0, 28，（56）day vaccination schedule
Normal saline
Normal saline administered intramuscularly according to a 0, 28 ，（56）day vaccination schedule
Aluminum adjuvant
Aluminum adjuvant administered intramuscularly according to a 0, 28，（56） day vaccination schedule
qixian Center for Disease Control and Prevention, Hebi
Lanzhou Institute of Biological Products Co., Ltd
INDUSTRY
Beijing Zhong Sheng Heng Yi Pharmaceutical Technology Co., Ltd.
UNKNOWN
Zhengzhou University
OTHER
National Vaccine and Serum Institute, China
INDUSTRY